Barclays PLC Grows Stake in LifeVantage Co. (NASDAQ:LFVN)

Barclays PLC boosted its holdings in LifeVantage Co. (NASDAQ:LFVN) by 38.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,966 shares of the company’s stock after buying an additional 11,608 shares during the quarter. Barclays PLC owned 0.34% of LifeVantage worth $507,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LFVN. Renaissance Technologies LLC raised its holdings in LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after acquiring an additional 17,300 shares during the period. Capital Management Corp VA purchased a new stake in shares of LifeVantage in the third quarter valued at approximately $5,073,000. HighTower Advisors LLC bought a new stake in shares of LifeVantage in the third quarter valued at about $638,000. Finally, Ritholtz Wealth Management lifted its holdings in LifeVantage by 62.0% during the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after buying an additional 10,974 shares during the period. 35.32% of the stock is owned by institutional investors.

LifeVantage Stock Performance

NASDAQ LFVN opened at $17.66 on Friday. The stock’s fifty day moving average is $14.96 and its two-hundred day moving average is $10.94. LifeVantage Co. has a fifty-two week low of $5.22 and a fifty-two week high of $19.06. The firm has a market capitalization of $221.19 million, a P/E ratio of 55.19 and a beta of 0.87.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $47.21 million for the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend was Monday, December 2nd. LifeVantage’s payout ratio is currently 50.00%.

Wall Street Analyst Weigh In

Separately, Lake Street Capital started coverage on shares of LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 target price on the stock.

LifeVantage Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.